Christianne Persenaire

Dr. Christianne Persenaire


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Open access
CPChristianne Persenaire
Christianne Persenaire
APAdam Pyrzak
Adam Pyrzak
EBEmma L. Barber
Emma L. Barber
To evaluate the effect of surgical approach on overall survival (OS) for women with advanced, epithelial ovarian cancer (EOC) following neoadjuvant chemotherapy (NACT) and determine the socio-demographic and clinical factors associated with surgical approach. The primary exposure was surgical approach to interval cytoreduction, minimally invasive versus open, and was evaluated by intention to treat. Primary outcome was OS. Associations were examined using Chi-squared tests, Wilcoxon rank sum tests, and multivariate logistic regression. Survival analysis was performed with Kaplan-Meier methods and Cox proportional hazards. The National Cancer Database was used to identify women diagnosed with stage IIIC/IV EOC from 2010–2016. Patients were included if they were treated with NACT within 90 days of diagnosis prior to interval cytoreductive surgery (CRS). 8,085 women were identified; 6,713 (83%) underwent open interval CRS and 1,372 (17%) underwent minimally invasive interval CRS. The proportion undergoing minimally invasive CRS after NACT increased from 2% in 2010 to 11% in 2016, a nearly 6-fold increase. There was no difference in OS between women who underwent minimally invasive and open interval CRS (median OS 36.5 vs 35.2 months, HR 0.94, 95% CI 0.86–1.04). After adjusting for demographic and clinical variables, including age, race, ethnicity, income, and Charlson/Deyo score, no difference in OS was observed (HR 0.95, 95% CI 0.86–1.04). Women of older age (OR 1.35, 95% CI 1.05–1.74) and Hispanic ethnicity (OR 1.46, 95% CI 1.14–1.88) had increased odds of receiving minimally invasive CRS following NACT, while low income (<$38,000/year) women had decreased odds (OR 0.76, 95% CI 0.60–0.97, p=0.03). Length of stay differed for patients undergoing minimally invasive versus open interval CRS (3 vs 5 days, p<0.01), but there was no difference in need for postoperative readmission. Minimally invasive CRS has similar survival outcomes to open CRS among women with EOC who have undergone NACT.

4 October 2023 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
CPChristianne Persenaire
Christianne Persenaire
DSDaniel L. Spinosa
Daniel L. Spinosa
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker
CLCarolyn J. Lefkowits
Carolyn J. Lefkowits

14 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CPChristianne Persenaire
Christianne Persenaire
BBBenjamin Bitler
Benjamin Bitler
BCBradley R. Corr
Bradley R. Corr
Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for patients with non-homologous recombination deficient (HRD) disease. Folate receptor alpha (FOLR1/FRα)-targeting agents have shown promise both alone and in combination with available therapies, but the relationship of FRα to other treatment-driving biomarkers is unknown. The Cancer Genome Atlas (TCGA) was queried to assess protein and mRNA expression and mutational burden in patients with differential FRα protein-expressing ovarian tumors, and the results referenced against the standard 324 mutations currently tested through FoundationOne Companion Diagnostics to identify targets of interest. Of 585 samples within TCGA, 121 patients with serous ovarian tumors for whom FRα protein expression was quantified were identified. FRα protein expression significantly correlated with FOLR1 mRNA expression (p=7.19×10 - 14 ). Progression free survival (PFS) for the FRα-high group (Q1) was 20.7 months, compared to 16.6 months for the FRα-low group (Q4, Logrank, p=0.886). Overall survival (OS) was 54.1 months versus 36.3 months, respectively; however, this result was not significant (Q1 vs. Q4, Logrank, p=0.200). Mutations more commonly encountered in patients with high FRα-expressing tumors included PIK3CA and FGF family proteins. Combinations of FRα-targeting agents with PI3K, mTOR, FGF(R) and VEGF inhibitors warrant investigation to evaluate their therapeutic potential. Simple Summary: Epithelial ovarian cancer can be highly lethal, with limited therapeutic options for patients without BRCA mutations or non-homologous recombination deficient disease. Folate receptor alpha (FRα)-targeting agents have shown promise in the setting of platinum-sensitive and platinum-resistant ovarian cancer, both alone and in combination with available therapies, but the relationship of FRα to other treatment-driving biomarkers is unknown. This study identifies potential targetable mutations in FRα-expressing tumors, including PIK3CA and FGF/R family proteins, and provides a basis for future investigations of novel combinations of FRα-targeting agents with PIK3CA, mTOR, FGF/R, and VEGF inhibitors.

15 September 2023 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
CPChristianne Persenaire
Christianne Persenaire
LBLisa Marie Babayan
Lisa Marie Babayan
KGKelsey Goon
Kelsey Goon
DSDaniel Spinosa
Daniel Spinosa
JSJeanelle Sheeder
Jeanelle Sheeder
LBLindsay Wheeler Brubaker
Lindsay Wheeler Brubaker